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Abstract
Type I allergy is an immunoglobulin E (IgE)-mediated chronic disease. As such, dis-
ease diagnosis and identification of targeted allergens are primarily based on specific 
IgE reactivity. Over the past decades, the contribution of T cells in allergy pathogen-
esis has been extensively studied. T cells are not only significant for the onset and 
maintenance of allergic disease but likely also play a key role for the induction of 
tolerance by allergen-specific immunotherapy (AIT). Due to the complexity of allergic 
T cell responses, epitopes have only been thoroughly mapped for the most dominant 
and prevalent allergens. Recently developed laboratory approaches enable us to per-
form thorough peptide screens, identifying T cell epitopes in known and novel aller-
genic targets, irrespective of their IgE reactivity. Monitoring allergen-specific T cells 
and their phenotype will provide insights into disease manifestation and progression 
on a molecular level.
However, performing such experiments in the clinic is not feasible. The definition of 
dominant T cell epitopes will allow us to create a tool to assess allergen-specific T cells 
in the context of different disease severities, such as rhinitis, asthma, and/or immuno-
therapy which will likely hold the key for improved diagnostic, biomarkers, and even 
novel therapeutic approaches.
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1. Introduction
Type I allergy is an immunoglobulin E (IgE)-mediated chronic disease. As such, disease diag-
nosis and identification of targeted allergens are primarily based on specific IgE reactivity. 
Specifically, clinical practices for the diagnosis of allergic disease are most commonly based 
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on skin prick testing [1], which typically involves pricking the skin with a needle or pin con-
taining a small amount of allergen [2]. A second diagnostic test is commonly performed in 
vitro for allergen-specific immunoglobulin E (IgE), which can accurately evaluate and quan-
tify the presence or absence of IgE specific for the whole allergen extract or single protein 
components [3].
The importance of IgE in mediating allergic disease, especially immediate-type reactions 
occurring within minutes of exposure to the allergen, is evident. However, the involvement 
of allergen-specific T cells and their pathological role in mediating late-phase reactions [4, 5] 
is often underappreciated. Allergenic proteins are defined based on their ability to bind IgE 
and the frequency of allergic patients harboring specific IgE antibodies to a given allergen 
[6, 7]. The potential of an allergenic protein to induce T cell reactivity is mostly not taken 
into account when classifying a protein as an allergen. Over the past decades, however, the 
contribution of T cells, specifically T helper 2 (Th2) cells, in mediating the pathogenesis of 
allergy has been extensively studied [8]. Immunological studies have shown that T cells play 
a key role early on, before allergic disease is even established. Susceptible individuals initially 
exposed to allergen mount a dominant Th2 response, resulting in the production of type 2 
cytokines, such as IL-4 and IL-13. These cytokines along with a direct physical interaction of 
T and B cells occurring between CD40L expressed on the surface of the activated T cell and 
CD40 constitutively expressed by B cells provide the signal for B cells to undergo antibody 
class switching and produce allergen-specific IgE [9, 10], a process referred to as allergic sensi-
tization. Subsequently, IgE molecules now present in high abundance bind with high affinity 
to Fcε receptors expressed on granulocytes, where they are cross-linked by allergen molecules 
upon reexposure, leading to mediator release and immediate-type symptoms, such as urti-
carial, allergic rhinitis, and conjunctivitis. Immediate-type reactivity is followed by late-phase 
reactions, which typically occur several hours/days after exposure to allergen. During the 
late-phase reaction, the affected tissue is infiltrated by Th2 cells and other inflammatory cells 
including eosinophils and neutrophils, which secrete high levels of cytokines, such as IL-4 
and IL-5 to promote inflammation [8].
T cells are not only significant for the onset and maintenance of allergic disease but likely 
also play a key role for the induction of tolerance, which can be achieved by allergen-specific 
immunotherapy (AIT) and is the only curative treatment for allergic disease to date. Due to the 
complexity of human T cell responses against allergens, epitopes have only been thoroughly 
mapped for the most dominant and prevalent allergens. Recently developed laboratory 
approaches enable us to perform thorough peptide screens, which achieve the identification 
and immunological characterization of T cell epitopes in known and novel allergenic targets, 
irrespective of their IgE reactivity [11, 12]. Mapping of T cell epitopes is of high importance: 
it greatly facilitates the detection, immunological analysis, and phenotypic characterization 
of allergen-specific T cells in patients suffering from allergic or asthmatic disease as well 
as providing a tool to monitor the efficacy of allergen-specific immunotherapy (AIT) treat-
ment. While allergen extracts can also be used to stimulate allergen-specific T cell responses, 
extracts are not standardized resulting in great variability of allergen content between extract 
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batches [13–15], and endotoxin content is often not monitored [16]. Further, processing and 
presentation of a large number of peptides present in extract limit the abundance of peptides 
that represent dominant T cell epitopes. It has been reported that allergen-specific T cells in 
tissues and peripheral blood are of very low frequency [17, 18], ranging from approximately 
10−5 to 10−3 CD4+ T cells, outside or within the pollen season, respectively. The rarity of these 
cells poses a great challenge for immune mechanistic studies designed to probe how allergic 
pathology or tolerance induction during AIT administration is orchestrated. The identifica-
tion of dominant T cell epitopes can therefore be of great importance not only to understand 
the molecular entities targeted by allergen-specific T cells but also to use them as a tool to 
detect, isolate, and characterize allergen-specific T cells.
The frequency of patients harboring IgE responses against a specific allergen is most often known 
and used for classification of the allergen as a minor or major allergen in a respective population 
[19, 20]. In contrast, T cell epitope data is only available for a small subset of allergens listed by 
the International Union of Immunological Society (IUIS) database [12]. The relative lack of data 
on allergen T cell epitopes is likely due to the highly complex nature of T helper cell responses 
in allergic disease, which makes it a difficult system for immunological studies. Moreover, aller-
gen-specific T cells occur at a very low frequency in the peripheral blood [18], making them 
hard to detect and isolate. Nevertheless, immunological studies on the allergic T cell response in 
humans have become of growing importance over the last years. Accordingly, new technologies 
and concepts have been developed to overcome the challenges of studying allergen-specific T 
cell responses, map single epitopes, and phenotypically characterize peptide-specific T cells to 
gain more insights into how T cells contribute to the pathology of allergy and asthma.
2. Challenges of T cell epitope mapping
The identification of T cell epitopes from major allergens is an important goal in allergy 
research. A critical step for inducing a T cell response against an allergen is the recognition of 
allergen-derived peptides. These peptides are presented to the T cell by antigen-presenting 
cells (APCs), such as dendritic cells or monocytes, in the context of major histocompatibility 
complex (MHC) class II molecules, which are constitutively expressed by APCs. MHC class 
II molecules are encoded by three different loci, designated HLA DR, DQ, and DP. Each of 
these three loci is extremely polymorphic adding a high degree of complexity, which has to 
be accounted for in the design of T cell epitope mapping strategies [21].
2.1. Overlapping versus predicted peptide
To identify T cell epitopes in allergy, the most diligent approach involves testing overlapping 
peptides that span the entire sequence of the allergen of interest. For this setup, the entire 
allergen sequence is broken down into short peptides, typically 12–20 amino acids in length, 
overlapping by 9–12 residues. These peptides are then tested for their ability to induce T cell 
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reactivity, using peripheral blood mononuclear cells (PBMCs) from allergic patients, often after 
in vitro expansion with allergen or allergen extract [22, 23]. Peptides that elicit T cell reactivity, 
as measured by cytokine production, proliferation, or upregulation of T cell activation mark-
ers, are reported as T cell epitopes. T cell epitope mapping using overlapping peptides is a 
very thorough approach, designed to identify any possible T cell-activating region within the 
allergen. However, mapping peptides for bigger allergens or even multiple allergens can add 
up to a very high number of peptides to test, also increasing the amount of blood needed for 
screening and the cost and effort associated. To make large-scale epitope identification more 
feasible, an approach was developed that involves preselection of peptides based on their abil-
ity to bind human MHC class II molecules. MHC molecules have a relatively broad specific-
ity for peptide binding. The three-dimensional structure forms a binding cleft that can bind 
peptides of varying length, typically ranging from 15 to 25 amino acids [24, 25]. The capacity 
of a peptide ligand to bind MHC class II molecules can be quantitatively measured directly 
by assessing its ability to inhibit the binding of a radiolabeled probe peptide to purified MHC 
molecules [26]. However, such experiments are labor intensive and expensive; therefore, com-
putational tools are continuously being developed to model and predict peptide-MHC binding 
[27, 28]. Using predicted peptide binding as a preselection criterion to decrease the number 
of peptides to screen for T cell epitope identification is less thorough than using overlapping 
peptides and may therefore increase the risk of missing T cell-reactive peptides. However, it 
has been reported that it is a reliable approach to identify the vast majority of T cell epitopes 
[28, 29], and it has been successfully used in several allergen systems, including Timothy grass 
[11], German cockroach [30], house dust mite [31], and others [32], to perform large-scale epi-
tope identification studies. Therefore, the decision between using overlapping and predicted 
peptides is likely dictated by the size and number of allergens studied as well as the amount of 
cells available from the clinical cohort.
2.2. Allergen-specific T cell frequencies
Another challenging aspect of T cell epitope identification in allergy is the low frequency of 
allergen-specific T cells. A study that evaluated the ex vivo frequency of T cells specific for Fel 
d 1, the major cat allergen, reported that the percentage of CD4+ T cells specific for a single Fel 
d 1 epitope ranged from 0.014 to 0.0003% in allergic individuals [33]. Another study, focused 
on Mugwort allergy, reported an ex vivo frequency of peptide-specific T cells of 0–0.029% in 
allergic cohort [34]. In a third study, performed with cells from patients allergic to Timothy 
grass, the authors reported epitope-specific T cell frequencies of 0.6–0.75% of the total CD4+ 
T cell subset [35], with a modest increase in frequencies detected during grass pollen season. 
The rarity of allergen-specific T cells poses a great challenge for epitope identification, as it will 
require the T cell reactivity assay to reliably detect a few single cells that respond to the peptide 
among several thousands of CD4+ T cells. In addition, a large amount of blood volume would 
be required to screen a given number of peptides. To bypass this problem, in vitro expansion 
cultures are performed, in which lymphocytes from allergic individuals are cultured over a 
few days or weeks with allergen extract or recombinant allergen protein to which the donor is 
allergic. The allergen in the culture will activate and stimulate the few antigen-specific T cells 
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present in the culture, causing them to proliferate. Typically, recombinant human IL-2 is added 
in limiting dilution in regular intervals after the first few days of culture to increase proliferation 
of allergen-specific cells, which have upregulated their IL-2 receptor during cell activation. Over 
time, allergen-specific cells, which were rare in the starting culture, become highly enriched due 
to antigen-specific stimulation and proliferation. After several days, the cells can be harvested in 
screened for T cell reactivity in response to restimulation with single peptides. In the presence of 
allergen or whole allergen extract, allergen peptide-specific T cells will have expanded and are 
now present in high abundance, making them easily detectable after restimulation with single 
peptides. T cell reactivity I response to a peptide can be measured by a variety of assays, most 
commonly using proliferation, cytokine production, or upregulation of activation marker as a 
readout [22, 36, 37]. This method is extremely useful to expand very rare antigen-specific CD4+ 
populations. However, one major limitation associated with in vitro expansion culture is that it 
changes the original phenotype of the cells. Therefore, it cannot be performed if an immunologi-
cal characterization of the phenotype of the antigen-specific cells is desired. Analyses designed 
to investigate the genetic expression profile have to be performed on cells isolated directly ex 
vivo, which is difficult due to their aforementioned rarity in the peripheral blood.
3. Immunological characterization of allergen-specific T cells
There are several approaches to isolate allergen-specific cells ex vivo for subsequent down-
stream immunological profiling using technologies, such as RNA or TCR sequencing. These 
technologies have become of increasing importance in areas, such as biomarker discovery or 
developing tools to monitor the efficacy of allergen-specific immunotherapy.
3.1. MHC tetramer assay
The use of MHC tetramer reagents to detect antigen-specific T cells is a well-established tech-
nique that allows detection and further downstream analysis of allergen-specific cells on a 
single cell level. The tetramer molecule is made up of a fluorescently labeled, centric strep-
tavidin molecule bound to biotin-labeled MHC molecules, which are loaded with a peptide 
known to be a T cell epitope to form the peptide-MHC complex (Figure 1A) [38]. The result-
ing tetramer can then be used as a reagent to bind T cells that are specific for both, the MHC 
type and peptide used in the tetramer (Figure 1B). Cells that are specific and bind the tetra-
mer are now fluorescently labeled and can be detected and isolated using a flow cytometer. 
There are several applications for tetramer staining all based on the premise that it allows the 
detection of single antigen-specific cells, even if they occur at low frequency. In vaccinology, 
tetramers are often used to track frequencies of peptide-specific T cells in the blood before and 
after vaccination or boost. Similarly, in allergy, tetramers have been used to quantify numbers 
of specific T cells as a variable of allergen season [35], allergen-specific immunotherapy [39], 
and disease status [34, 40]. In addition, tetramer staining can be combined with other method-
ologies to perform more detailed immunological characterization of allergen-specific T cells. 
Simultaneous assessment of cell proliferation, cytokine production, or activation can provide 
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functional information in addition to knowing the peptide specificity and MHC restriction 
of the cell. Tetramer reagents can even be used for T cell epitope mapping. This approach 
involves loading empty MHC molecules with pools of mixtures of overlapping peptides from 
the allergen of interest, each pool typically containing 5–10 peptides. These tetramers are then 
screened with PBMC that have been cultured with the allergen of interest. Pools that posi-
tively detect T cell populations are deconvoluted into single peptides, which are loaded onto 
MHC molecules individually and then analyzed to identify single epitopes. Tetramers that 
return positive stainings automatically provide a population of T cells with a known MHC 
restriction and antigen specificity, which can be sorted by fluorescence-activated cell sorting 
(FACS) allowing downstream analysis of phenotype and genotype. This approach has suc-
cessfully been used in allergy to identify T cell epitopes [41].
MHC tetramer assays represent a revolution for the study of antigen-specific T cells, providing 
an efficient way to directly visualize, quantify, phenotype, and isolate T cells of interest. Yet, this 
technology is also associated with disadvantages and limitations. The construction of tetramer 
reagents is not trivial and requires an advanced level of expertise. Production and purification of 
high-quality MHC molecules are labor intensive, and only a subset of MHC alleles expressed by 
humans is available as tetramer. Further, the use of tetramers requires existing knowledge about 
the HLA restriction of the peptide of interest. In allergy, many dominant T cell epitopes are 
highly promiscuous, meaning they are restricted by multiple alleles, which makes finding their 
restriction more difficult. Determining the HLA restriction of given peptides can be done experi-
mentally, for example, by inhibition with locus-specific antibodies [32]. This method, however, 
only identifies the restricting locus. Data from HLA-binding assays can also be a useful tool 
to narrow down the possible restriction [42]. Another approach designed to determine HLA 
restriction at the allele level involved the use of single HLA class II-transfected cell lines [43]; 
however, a large panel of cell lines is required to determine restrictions in multiple donors due 
to the heterogeneity of HLA types in a given population. As an alternative to the experimental 
Figure 1. (A) Schematic representation of the structural complex of a MHC class II tetramer and (B) binding of tetramer 
molecules to the peptide-specific T cell via the T cell receptor (TCR).
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approaches, which are labor intensive and technically challenging, a bioinformatical predic-
tion tool was developed. This tool uses T cell response data in an HLA-typed population to 
infer HLA restriction by genetic association [44]. Although this tool streamlines the prediction 
of HLA restriction, it still requires experimental T cell response data and an HLA-typed popula-
tion large enough to make significant predictions possible.
The use of tetramer reagents requires preexisting knowledge about the HLA restrictions for a 
given peptide as well as the HLA type of the donor sample. Acquiring this information can be 
costly and labor intensive, making this approach less feasible for certain studies.
3.2. Cytokine capture assay
The isolation of antigen-specific cells based on cytokine production used to be complicated by 
the fact that T cells positive for cytokine production were detected by intracellular cytokine 
staining, which involved fixation and permeabilization of the cell. Fixed cells are no longer alive 
and can therefore not be used for downstream applications that require live cells, and even iso-
lation of DNA or RNA from fixed cells is somewhat more complex than from live cells. A new 
approach that captures cytokines on the cell surface immediately after secretion was developed 
to allow detection and isolation of viable cells that secrete cytokines in response to antigen 
stimulation. In this protocol, cells are pre-labeled with a “catch reagent,” a divalent complex 
consisting of a CD45-specific monoclonal antibody conjugated to monoclonal antibody directed 
against the cytokine of interest. The anti-CD45 antibody will bind to CD45 molecules expressed 
on the T cell surface and effectively coat the cell (Figure 2). Subsequently, cells are stimulated 
with antigen, and any cytokine produced will be bound to the cytokine-specific antibody conju-
gated to anti-CD45 immediately after secretion. Detection of cytokine-positive cells is achieved 
by using a fluorescent-labeled detection antibody with the same cytokine specificity but recog-
nizing a different epitope from the catch reagent antibody (Figure 2). If the antigen-specific T 
cell population is extremely rare, which is often the case in allergy and asthma, an enrichment 
step can be performed. To further enrich antigen-specific cells before flow cytometric analysis 
or isolation, microbeads conjugated to monoclonal antibodies specific for the respective fluoro-
phore used in the experiment can be used to label cells, followed by magnetic column enrich-
ment [35]. After cells are labeled and the enrichment step has been performed if desired, viable 
cells can be analyzed and isolated by flow cytometry, facilitating downstream applications, 
such as further culture assays or DNA/RNA extraction for sequencing analysis. A potential 
limitation of this assay is the bias introduced by isolating cells based on production of a sin-
gle cytokine. Often, cytokine production in response to allergens is heterogeneous, and cells 
produce different levels of different cytokines, such as IL-4, IL-5, IL-13, and sometimes IFNg. 
Detection of allergen-specific cells based on production of a single cytokine will likely lead to 
an underrepresentation of allergen-specific cells, since cells producing a different cytokine will 
not be detected.
3.3. Cell activation assays
Another hallmark of antigen-specific T cells is the upregulation of activation markers in 
response to antigen stimulation. Therefore, these activation markers can be targeted with 
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fluorescent antibodies to detect antigen or allergen-specific cells. The challenge of this approach 
is to identify activation markers that are specific and highly expressed to allow reliable 
detection of allergen-specific T cells even at low frequency. One molecule that has become 
very popular for such an application is CD154, also known as CD40 ligand (CD40L). CD154 
is a member of the tumor necrosis factor (TNF) superfamily and found to be primarily 
expressed on activated T cells, making it very specific. It acts as a co-stimulatory molecule, 
binding to CD40 on antigen-presenting cells, which can lead to several downstream events 
depending on the target cell type. Several studies designed to study allergen-specific effec-
tor cells in cohorts suffering from allergy, asthma, or who have been treated with AIT have 
successfully applied this methodology to immunologically characterize and isolate aller-
gen-specific T cells ex vivo [37, 45]. The caveat of using CD154 as a selection marker for acti-
vated, allergen-specific T cells is that it is also typically stained intracellularly. In humans, 
CD154 molecules expressed on the cell surface quickly become unstable, making a large 
number of CD154 expressing cells undetectable. Therefore, this assay typically involves 
fixation and permeabilization to allow intracellular staining of CD154, making downstream 
applications less feasible.
As an alternative to CD154, other activation markers, such as Ox40 and CD25 have also been 
used to detect and isolate antigen-specific cells after short-term antigen stimulation [46]. The 
main advantage of this approach is that both Ox40 and CD25 are stably expressed on the cell 
surface and therefore cells can be detected and isolated in viable form without the need of 
fixation or permeabilization. However, CD25 is also strongly expressed by regulatory T cells, 
irrespective of activation; therefore, gating of Ox40 and CD25 double-positive cells has to be 
performed with great accuracy, and the inclusion of a third marker, such as PDL-1 may be 
considered to avoid contamination of nonspecific T cells.
Figure 2. A schematic representation of the methodology involved for a cytokine capture assay, using IL-5 as repre-
sentative cytokine.
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3.4. Proliferation assays
The identification of antigen-specific cells based on the proliferative response to antigenic 
stimulation is perhaps the most classical approach and has been widely used for several 
applications including T cell epitope mapping, phenotypic characterization, T cell response 
kinetics, and others. In the past, the classic method to detect cell proliferation in response to 
allergen stimulation involved the addition of radioactive nucleoside, 3H-thymidine, to the 
culture, which would be automatically incorporated into new strands of chromosomal DNA 
during mitotic cell division. Subsequently, proliferation was assessed by measuring the radio-
activity in DNA recovered from the cell sample using a scintillation beta-counter. Though this 
technology is still used in some laboratories, proliferation is now more commonly detected by 
flow cytometry. One common approach is the staining of cells with a special fluorescent dye, 
which is then diluted through each cell division. This decrease in the concentration of the dye 
can be visualized by flow cytometry. Another approach is to stain stimulated cells with anti-
bodies targeting markers associated with proliferation, such as Ki67. The measure of prolifera-
tion in response to antigen stimulation is straightforward and inexpensive. The greatest caveat 
associated with using proliferation as a readout for antigen-specific reactivity is the relatively 
high rate of false positivity due to bystander activation. A study designed to directly compare 
the use of tetramer staining reagents versus allergen-induced proliferation for the detection of 
allergen-specific T cells found that while tetramers had a relatively low rate of sensitivity, cells 
identified based on proliferation contained extremely high fractions of bystander cells [34], 
making this approach more suitable if an enriched population is sufficient for the study rather 
than a desire for a pure antigen-specific population.
4. Targeting T cells in allergen-specific immunotherapy
Allergy and asthma are debilitating diseases that are most commonly treated using phar-
macotherapy which are designed to improve the symptoms but not the cause of disease. 
To date, the only disease-modifying therapy available is allergen-specific immunotherapy 
(AIT). First administered over a century ago [47], AIT has been widely demonstrated to be a 
clinically effective treatment, inducing immunological tolerance and improvement of clini-
cal symptoms beyond the time of treatment [48]. Despite its favorable duration of efficacy, 
a considerable effort is invested to improve current AIT protocols. Allergen-specific immu-
notherapy with whole extract can be associated with IgE-mediated adverse reactions that 
result from the patient’s allergen-specific IgE molecules being cross-linked by the allergen 
present in the extract used for treatment, triggering degranulation and immediate-type reac-
tions. The occurrence of such adverse events and the need for extended treatment periods 
that last several years can have a negative impact on treatment compliance. For this reason, 
researchers have strived to find a treatment that targets T cells and circumvents potential IgE 
reactivity. Removal of IgE epitopes, thereby eliminating the risk of IgE cross-linking, is one 
obvious approach. There are a variety of methods to achieve this goal, some of which have 
been evaluated in clinical trials.
Strategies to Study T Cells and T Cell Targets in Allergic Disease
http://dx.doi.org/10.5772/intechopen.68923
131
4.1. Peptide immunotherapy
One extensively pursued approach for AIT focused on T cells while omitting IgE epit-
opes is called peptide immunotherapy, where instead of using whole allergen extract, 
allergic patients are treated with a mixture of short, synthetic peptides that constitute 
the major T cell epitopes of the allergen the patient is allergic to. The clinical efficacy of 
peptide immunotherapy has been demonstrated in several Phase IIb double-blind, pla-
cebo-controlled trials [49, 50]. A significant reduction in symptoms, measured as the total 
rhinoconjunctivitis symptom score (TRSS), was observed following the administration of 
only eight intradermal injections of the peptide formulation. In this study, TRSS levels 
remained suppressed both at the 1- and 2-year follow-up time point [51]. The immuno-
logical mechanisms by which peptide immunotherapy induces tolerance are not yet fully 
understood. However, studies have reported a downregulation of pathological type 2 
cell responses and a concomitant increase in regulatory signals, such as the production 
of IL-10 in the periphery. Further, significant increases in IFNg-producing Th1 cells and 
CD25+ cells have been reported. The induction of IgG4-blocking antibodies, which are 
believed to contribute to clinical efficacy by occupying the allergen-binding sites, thereby 
preventing IgE-allergen binding, is a hallmark event during conventional AIT with aller-
gen extract. Interestingly, increased levels of IgG4 are rarely observed, probably due to 
the lack of conformational B cell epitopes decreasing the likelihood of B cell stimulation 
and resulting IgG production. Therefore, though modulatory events on the cellular level 
appear to be broadly similar to those believed to occur during extract-based AIT, humoral 
responses may be more distinct. Although peptide immunotherapy has been shown to 
be clinically effective, it is also associated with challenges that need to be addressed. The 
route of administration has been debated, and the clinical effects seem to be very sensitive 
to dosing. Lower doses may not induce tolerance due to lack of potency for induction of 
regulatory T cells, while too high dose may stimulate and expand pathogenic Th2 cells. 
The selection of peptides is also a factor of consideration. Typically, mixtures used for 
peptide immunotherapy include between 5 and 10 peptides. However, epitope specifici-
ties can be very heterologous in a given population, and therefore the selection may not 
be straightforward. The consideration of these factors and others make the development 
of peptide immunotherapy challenging at times.
4.2. Fragmented allergens
Another approach of AIT that was designed to target T cells while bypassing IgE binding 
to avoid IgE-mediated side effects is the generation of fragmented allergens. This approach 
was tested using the major birch pollen allergen, Bet v 1, as a model. The fragmentation of 
the allergen involved its division into non-IgE-binding fragments, which retain their T cell 
reactivity. Birch pollen allergic patients were then vaccinated with these hypoallergenic 
derivatives in a double-blind, placebo-controlled study. This vaccination was found to reduce 
cutaneous sensitivity, improve symptoms, and significantly reduce rises in birch-specific IgE 
levels during season in the active group compared to placebo [52]. However, immunological 
mechanisms and long-term efficacy were not evaluated.
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5. Concluding remarks
Allergic disease severity is very poorly understood. The degree of symptom manifestation, 
such as asthma versus rhinitis can often not be explained by allergen-specific IgE titers. There 
is a dire need for better diagnostics and biomarkers that will help us evaluate treatment 
options and disease prognosis. Gaining a better understanding of the immunological events 
on a cellular level may have a tremendous impact on how we treat patients in the clinic. 
Monitoring allergen-specific T cells and their phenotype will provide insights into disease 
manifestation and progression on a molecular level. However, performing such experiments 
in the clinic is not feasible. The definition of dominant T cell epitopes will allow us to create a 
tool to assess allergen-specific T cells in the context of different disease severities, such as rhi-
nitis, asthma, and/or immunotherapy which will likely hold the key for improved diagnostic, 
biomarkers, and even novel therapeutic approaches.
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